Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

DRUG

Bright Minds Biosciences Inc

Dec 13 • 01:47PM ET

41.44

Dollar change +1.94
Percentage change 4.91	%

Healthcare • Biotechnology • USA • NASD

Peers: CMPS MNMD ATAI SAGE NBIX CYBN RLMD GHRS LPTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.68	Insider Own	27.24%	Shs Outstand	6.95M	Perf Week	7.61%
Market Cap	288.01M	Forward P/E	-	EPS next Y	-4.40	Insider Trans	47.19%	Shs Float	5.06M	Perf Month	-1.73%
Income	-2.63M	PEG	-	EPS next Q	-0.63	Inst Own	41.55%	Short Float	23.03%	Perf Quarter	3241.94%
Sales	0.00M	P/S	-	EPS this Y	-365.45%	Inst Trans	-	Short Ratio	0.39	Perf Half Y	3693.14%
Book/sh	1.00	P/B	41.50	EPS next Y	-20.12%	ROA	-47.96%	Short Interest	1.17M	Perf Year	2787.80%
Cash/sh	0.65	P/C	63.72	EPS next 5Y	-	ROE	-51.16%	52W Range	0.93 - 79.02	Perf YTD	2797.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-137.36%	ROI	-59.08%	52W High	-47.56%	Beta	-6.92
Dividend TTM	-	Quick Ratio	35.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	4355.91%	ATR (14)	4.69
Dividend Ex-Date	-	Current Ratio	35.08	EPS Y/Y TTM	64.64%	Oper. Margin	-	RSI (14)	54.35	Volatility	7.22% 11.66%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	53.62
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	112.54%	Payout	-	Rel Volume	0.06	Prev Close	39.50
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	3.01M	Price	41.44
SMA20	6.19%	SMA50	13.48%	SMA200	314.17%	Trades		Volume	120,240	Change	4.91%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-24	Initiated	Robert W. Baird	Outperform	$75

Nov-21-24 09:00AM	Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting (GlobeNewswire)
Nov-06-24 06:30AM	Bright Minds Biosciences Secures $35 Million Investment (TipRanks)
Nov-04-24 02:41PM	Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement (GlobeNewswire) +5.00%
Oct-21-24 08:30AM	Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data (GlobeNewswire)
Oct-18-24 06:50AM	Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement (GlobeNewswire) +117.56%
10:45AM	Loading…
Oct-16-24 10:45AM	Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models (GlobeNewswire) -25.18%
09:20AM	Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA Technology (GlobeNewswire)
05:57AM	Biotech stock tumbles after unexplained 1,446% gain (MarketWatch)
Oct-15-24 09:09PM	Bright Minds is Unaware of Any Material Changes (Newsfile) +1,445.78%
Oct-03-24 09:00AM	Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events (GlobeNewswire)
Sep-19-24 10:00AM	Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th (GlobeNewswire)
Sep-12-24 08:00AM	Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy (PR Newswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-20-24 11:53AM	DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024 (InvestorPlace)
Dec-06-23 05:08PM	Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management (PR Newswire) +5.53%
06:50AM	Loading…
Aug-08-23 06:50AM	Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) +29.50%
Jul-20-23 06:50AM	Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) -16.38%
Jul-11-23 06:50AM	Bright Minds Announces Effective Date of Share Consolidation (GlobeNewswire)
Jun-22-23 06:50AM	Bright Minds Announces Proposed Share Consolidation (GlobeNewswire) +5.33%
Apr-19-23 06:50AM	Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 (GlobeNewswire) +26.08%
Apr-10-23 06:50AM	Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research (GlobeNewswire)
Feb-27-23 06:50AM	Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 (GlobeNewswire) -10.54%
Feb-17-23 06:50AM	Bright Minds Biosciences Announces Non-Executive Director Appointment (GlobeNewswire)
Feb-08-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements (GlobeNewswire) -6.58%
Jan-27-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire) -6.59%
Jan-09-23 04:05PM	Bright Minds Biosciences Announces Resignation of Board Member (GlobeNewswire) -7.46%
Dec-02-22 07:07PM	Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement (GlobeNewswire)
Nov-28-22 06:50AM	Bright Minds Biosciences Announces Non-Brokered Private Placement (GlobeNewswire) +10.78%
Nov-23-22 11:35AM	Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-07-22 06:50AM	Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors (GlobeNewswire)
06:50AM	Loading…
Aug-31-22 06:50AM	Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome (GlobeNewswire) -15.42%
Aug-30-22 03:35PM	Bright Minds Biosciences Announces Closing of $4 Million Unit Offering (GlobeNewswire) -23.05%
Aug-23-22 09:07PM	Bright Minds Announces Pricing of Overnight Marketed Offering of Units (GlobeNewswire) -38.43% +48.87%
Aug-22-22 07:05PM	Bright Minds Announces Overnight Marketed Offering of Units (GlobeNewswire) +72.80%
Aug-18-22 03:34PM	Bright Minds Biosciences Comments on Recent Trading Activity (GlobeNewswire) +121.43%
Jun-27-22 06:50AM	Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization (GlobeNewswire)
May-12-22 06:50AM	Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome (GlobeNewswire)
May-02-22 06:50AM	Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties (GlobeNewswire)
Apr-19-22 06:50AM	Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders (GlobeNewswire) +8.40%
Mar-14-22 06:50AM	Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial (GlobeNewswire)
Mar-08-22 07:30AM	Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-04-22 04:05PM	Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-15-21 05:13PM	Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone (Newsfile) +5.88%
Dec-06-21 06:50AM	Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference (GlobeNewswire)
Nov-30-21 07:30AM	Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases (GlobeNewswire) -8.35%

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	10% Owner	Nov 04 '24	Buy	21.70	184,331	3,999,983	1,059,331	Nov 06 04:20 PM
Cormorant Asset Management, LP	10% Owner	Oct 15 '24	Buy	5.53	372,591	2,061,574	825,000	Oct 17 05:11 PM
Cormorant Asset Management, LP	10% Owner	Oct 16 '24	Buy	23.46	50,000	1,172,813	875,000	Oct 17 05:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DRUG

Bright Minds Biosciences Inc

Upgrade your FINVIZ experience